TY - GEN
T1 - Overview and treatment of ibs with predominant constipation in women
AU - Flanagan, Mariel
AU - Spangler, Mikayla
N1 - Publisher Copyright:
© 2021, Jobson Publishing Corporation. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Irritable bowel syndrome with predominant constipation (IBS-C) is a chronic disorder that primarily affects women. In 2020, the first clinical guideline by the American College of Gastroenterology for the treatment of IBS was published. A variety of nonpharmacologic recommendations for IBS-C include gut-directed psychotherapy, psyllium fiber, peppermint oil, and a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Women with IBS-C have four FDA-approved prescription-treatment options including lubiprostone, linaclotide, plecanatide, and tegaserod. Selection of medication therapy may be guided by cost/insurance coverage, adverse-effect profile, and desired frequency of dosing.
AB - Irritable bowel syndrome with predominant constipation (IBS-C) is a chronic disorder that primarily affects women. In 2020, the first clinical guideline by the American College of Gastroenterology for the treatment of IBS was published. A variety of nonpharmacologic recommendations for IBS-C include gut-directed psychotherapy, psyllium fiber, peppermint oil, and a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Women with IBS-C have four FDA-approved prescription-treatment options including lubiprostone, linaclotide, plecanatide, and tegaserod. Selection of medication therapy may be guided by cost/insurance coverage, adverse-effect profile, and desired frequency of dosing.
UR - http://www.scopus.com/inward/record.url?scp=85115659445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115659445&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85115659445
VL - 46
SP - 26
EP - 33
JO - U.S. Pharmacist
JF - U.S. Pharmacist
SN - 0148-4818
ER -